

Summary of minutes of EUCAST Steering Committee Meeting Milan, Italy, 10-11 May 2011

Attending

Dr Petra Apfalter	PA	EUCAST General Committee	Austria
Dr Derek F.J. Brown	DB	Scientific Secretary	United Kingdom
Dr Rafael Cantón	RC	Clinical Data Co-ordinator	Spain
Dr Christian Giske	CG	SRGA	Sweden
Dr Marina Ivanova	MI	EUCAST General Committee	Estonia
Prof Gunnar Kahlmeter	GK	Chairperson	Sweden
Prof Alasdair P. MacGowan	AM	BSAC	United Kingdom
Dr Johan W. Mouton	JM	CRG	The Netherlands
Prof Arne Rodloff	AR	DIN	Germany
Prof Claude-James Soussy	CS	CA-SFM	France
Dr Martin Steinbakk	MS	NWGA	Norway
Present for items 23 to 25			
Dr Radu Botgros	RB	EMA	United Kingdom
Dr Mair Powell	MP	MHRA	United Kingdom
Prof Irja Lutsar	IL	CHMP	Estonia

1	Chairman's welcome
2	Minutes of meeting of 15-16 February 2011 The minutes were accepted as a correct record.
3	<p>Matters arising from minutes of 15-16 Feb 2011 (items not covered by agenda) A paper explaining ECOFFs is in preparation and will be submitted to CMI.</p> <p>MIC distributions for <i>C. difficile</i> have been added to the MIC database.</p> <p>EMA will be asked for a view on EUCAST setting breakpoints for agent-organism combinations for which there is no marketing approval. Comments on the draft EMA "Guideline on the Evaluation of Medicinal Products indicated for Bacterial Infections" have been sent to EMA.</p> <p>A draft paper explaining Pk/Pd breakpoints has been prepared.</p> <p>Gonococcal susceptibility testing methods are being investigated.</p> <p>A proposal to change cefixime breakpoints for <i>N. gonorrhoeae</i> is in progress.</p> <p>Photographs and notes on testing <i>S. aureus</i> for β-lactamase production are being prepared.</p>
4	New agents A new glycopeptide is likely to receive marketing approval in the near future. A new cephalosporin is being assessed. Fidaxomicin has been deferred by EMA. An application for extension of indications for a fluoroquinolone has been withdrawn by the company.
5	Status of EUCAST rationale documents The current status of documents was reviewed.
6	Breakpoint issues Fluoroquinolone breakpoints for viridians streptococci are being discussed.
7	Expert rules subcommittee Version 2 of the rules will soon be on the EUCAST website. The subcommittee will be disbanded.
8	<p>Antifungal susceptibility testing subcommittee Breakpoints and rationale documents for posaconazole, anidulafungin and amphotericin B have been released. Juan Luis Rodriguez-Tudela and Peter Donnelly have resigned from the subcommittee and have been replaced by Maiken Arendrup (Chair) and William Hope (Scientific Secretary).</p>
9	Anaerobe subcommittee Interim results of a study of susceptibility testing methods were reviewed.

10	<p>Organisms without EUCAST breakpoints <i>H. pylori</i> breakpoints and <i>C. difficile</i> ECOFFs will be released. Projects on <i>Legionella</i> spp., <i>Listeria</i> spp., <i>Campylobacter</i> spp., <i>P. multocida</i>, <i>B. cepacia</i>, <i>Actinomycetes</i> spp., <i>Nocardia</i> spp., <i>Corynebacterium</i> spp. and <i>S. maltophilia</i> are in progress.</p>
11	<p>ESCMID Proposals for sessions at ECCMID 2012 and for a Postgraduate Educational Course in Madrid in September 2012 will be sent to ESCMID.</p> <p>It was noted that an ESCMID Mycobacterium study group has been set up.</p>
12	EMA No new information.
13	CLSI No new information.
14	ECDC No new information.
15	<p>Implementation of EUCAST breakpoints Maps of country status regarding National Antimicrobial Susceptibility Testing Committees, implementation of breakpoints and implementation of the disk diffusion test are being developed.</p> <p>Validation of gradient tests on MH-F medium remains an issue.</p> <p>Breakpoints for topical agents are to be discussed.</p> <p>A questionnaire on national doses of antimicrobial agents will be prepared.</p> <p>The review of <i>Moraxella catarrhalis</i> breakpoints was completed and breakpoints will be released.</p> <p>The format for MIC dilution series will be in line with that used by CMI, JAC and ASM journals.</p>
16	EUCAST statutes The revised statutes will be published on the EUCAST website.
17	Website No new information.
18	Co-amoxiclav breakpoints and susceptibility testing Publications or unpublished clinical data correlating outcome with an amoxicillin/clavulanate breakpoint of 8/4 mg/L are not available.
19	Direct antimicrobial susceptibility testing Guidelines will be prepared.
20	Cefoxitin for detecting methicillin resistance in coagulase-negative staphylococci There was good correlation of cefoxitin zone diameters with confirmed <i>mecA</i> status in a recent study.
21	Ciprofloxacin breakpoints for <i>Salmonella</i> spp. The reliability of a ciprofloxacin disk diffusion test for detecting reduced susceptibility is being investigated.
22	Breakpoints splitting the wild type Discrepancies are being investigated.
23-25	New cephalosporin The agent was presented by the company.
26	Any other business None
27	<p>Next meetings 26-27 September 2011, Berlin, Germany (to be confirmed). 21-22 November 2011, Brussels, Belgium 30-31 January 2012, Paris, France 3-4 April 2012, London, UK (after ECCMID) 9-10 July 2012, Stockholm, Sweden 24-25 September 2012, Madrid, Spain</p>

Ratified summary of minutes of meeting 10-11 May 2011. Prepared by DB, GK and RC